Overview

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Manhattan Pharmaceuticals
Treatments:
Estrone
Estropipate
Oleoyl-estrone